Part VI: Summary of the risk management plan

Summary of risk management plan for Tafluprost Santen 15 microg/ml eye drops, solution in single-dose container (tafluprost)

This is a summary of the risk management plan (RMP) for Tafluprost Santen 15 microg/ml eye drops, solution in single-dose container. The RMP details important risks of Tafluprost Santen, how these risks can be minimised, and how more information will be obtained about Tafluprost Santen's risks and uncertainties (missing information).

Tafluprost Santen's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Tafluprost Santen should be used.

I. The medicine and what it is used for

Tafluprost Santen is authorised for the reduction of elevated intraocular pressure in open angle glaucoma and ocular hypertension (see SmPC for the full indication). It contains tafluprost as the active substance and it is given by ophthalmic administration.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Tafluprost Santen, together with measures to minimise such risks and the proposed studies for learning more about Tafluprost Santen's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine’s packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine’s legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

II.A List of important risks and missing information

Important risks of Tafluprost Santen are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Tafluprost Santen. Potential risks are concerns for which an association

with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

List of important risks and missing information	
Important identified risks	None
Important potential risks	None
Missing information	None

II.B Summary of important risks

Not applicable.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Tafluprost Santen eye drops, solution in single-dose container.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Tafluprost Santen eye drops, solution in single-dose container.